SOTHEMACAS:SOT -0.12%71 Pretax Margin % is 19.19% as of Dec. 2025, which is 6% above its 10-year median of 18.18. GuruFocus rates CAS:SOT with a GF Score™ of 71/100 and a GF Value™ of MAD284.90 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, SOTHEMA ranks better than 80.1% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. SOTHEMA's Pre-Tax Income for the
six
months ended in Dec. 2025 was MAD322 Mil. SOTHEMA's Revenue for the
six
months ended in Dec. 2025 was MAD1,676 Mil. Therefore, SOTHEMA's pretax margin for the quarter that ended in Dec. 2025 was 19.19%.
The historical rank and industry rank for SOTHEMA's Pretax Margin % or its related term are showing as below:
CAS:SOT'
s Pretax Margin % Range Over the Past 10 Years
Min: 15.42 Med: 18.18 Max: 19.82
Current: 19.39
CAS:SOT's Pretax Margin % is ranked better than 80.1% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs CAS:SOT: 19.39
SOTHEMA (CAS:SOT) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
SOTHEMA Pretax Margin % Related Terms
SOTHEMA Pretax Margin % Historical Data
* Premium members only.
The historical data trend for SOTHEMA's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS:SOT vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, SOTHEMA's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where SOTHEMA's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a Pretax Margin % of 19.19% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SOTHEMA and its competitors. This is near median its historical median of 18.18. Over the past decade, SOTHEMA's Pretax Margin % has ranged from 15.42 to 19.82. According to the industry distribution chart, SOTHEMA ranks #190 out of 955 companies in the Drug Manufacturers industry, placing it in the top 19.9%.
Is SOTHEMA's Pretax Margin % too high?
SOTHEMA's current Pretax Margin % of 19.19% is near median its 10-year median of 18.18. Over the past 10 years, this metric has ranged from a low of 15.42 to a high of 19.82. The Drug Manufacturers industry median Pretax Margin % is 7.28. SOTHEMA's value of 19.19% is 163.6% above this industry median. Based on the distribution chart, SOTHEMA ranks #190 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SOTHEMA has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SOTHEMA ranks #190 out of 955 companies for Pretax Margin %. This places SOTHEMA in the top 20% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. SOTHEMA's value of 19.19% is 163.6% above this benchmark. Historically, SOTHEMA's own Pretax Margin % has ranged from 15.42 to 19.82 over the past decade. While the company's 10-year median is 18.18 vs. the industry median of 7.28, SOTHEMA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOTHEMA's current Pretax Margin % of 19.19% is 163.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SOTHEMA and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOTHEMA's current Pretax Margin % is 19.19%, which is near median its own 10-year median of 18.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Significantly Overvalued. The stock's GF Value™ is MAD284.90, compared to a current price of MAD379.50 — trading 33.2% above its estimated fair value. The current Pretax Margin % is 19.19%, which is near median its 10-year median of 18.18 and 163.6% above the Drug Manufacturers industry median of 7.28. SOTHEMA's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current Pretax Margin % is 19.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD379.50 is trading 33.2% above its estimated GF Value™ of MAD284.90.
GuruFocus considers SOTHEMA to be Significantly Overvalued.
Key valuation signals for CAS:SOT:
Pretax Margin %: 19.19% (near median its 10-year median of 18.18)
GF Value™: MAD284.90 vs. price of MAD379.50 (33.2% above fair value)
Industry Position: 163.6% above the Drug Manufacturers median (#190 of 955)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
71GF Score
Get the complete analysis for CAS:SOT
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
